Amgen Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 18, 2007--Amgen
(NASDAQ:AMGN) has been notified of an unsolicited "mini-tender offer"
by TRC Capital Corporation (TRC) to purchase up to 1,500,000 shares of
its common stock, representing less than 0.13 percent of Amgen's
outstanding shares, at a price of $53.75 per share.
Amgen does not endorse TRC's unsolicited mini-tender offer and
recommends that stockholders not tender their shares in response to
this mini-tender offer. Amgen wants all stockholders, broker-deals and
other market participants to be clear that Amgen is not associated in
any way with TRC, this mini-tender offer or the offer documentation.
Amgen understands that TRC has made numerous unsolicited
mini-tender offers in the past for stock of other companies.
Mini-tender offers, such as this one by TRC, are offers to acquire
less than 5 percent of a company's outstanding shares and thereby
avoid many procedural and disclosure requirements of the federal
securities laws that protect investors, including the filing of tender
offer documents with the Securities and Exchange Commission.
Amgen urges investors to:
-- Obtain current market quotes for their shares of common stock,
-- Consult with their financial advisors, and
-- Exercise caution with respect to TRC's offer.
Amgen stockholders who already have tendered their shares are
advised that they may withdraw their shares by providing the written
notice described in the TRC Capital offering documents prior to the
expiration of the offer currently scheduled for 12:01 AM, Eastern Time
on June 8, 2007. TRC's original offer price of $60.10 per share
represented a 4.1 percent discount to the closing price on May 8,
2007, the day prior to the date of the offer. On May 18, 2007 TRC
reduced its offer price to $53.75, which represents a 1 percent
discount to the closing price on May 18, 2007. Please note that TRC
reserves the right to further reduce its offer price.
The SEC has issued "Investor Tips" on mini-tender offers, which
note that often in making the offers at below-market prices, "bidders
are hoping that they will catch investors off guard if the investors
do not compare the offer price to the current market price." The SEC's
advisory is available at www.sec.gov/investor/pubs/minitend.htm.
Amgen encourages stockbrokers and dealers as well as other market
participants to review the SEC's recommendations on the dissemination
of mini-tender offers. These recommendations are available at
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis and other serious illnesses. With
a deep and broad pipeline of potential new medicines, Amgen remains
committed to advancing science to dramatically improve people's lives.
To learn more about our pioneering science and our vital medicines,
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)